rs201486613
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 2P and 8B. PM2BP4_StrongBS1
The NM_007272.3(CTRC):āc.674A>Cā(p.Glu225Ala) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000255 in 1,614,184 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. E225E) has been classified as Likely benign.
Frequency
Consequence
NM_007272.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CTRC | ENST00000375949.5 | c.674A>C | p.Glu225Ala | missense_variant | 7/8 | 1 | NM_007272.3 | ENSP00000365116.4 | ||
CTRC | ENST00000375943.6 | c.*128A>C | 3_prime_UTR_variant | 4/5 | 1 | ENSP00000365110.2 | ||||
CTRC | ENST00000483406.1 | n.438A>C | non_coding_transcript_exon_variant | 5/6 | 5 |
Frequencies
GnomAD3 genomes AF: 0.000210 AC: 32AN: 152176Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000437 AC: 110AN: 251450Hom.: 1 AF XY: 0.000456 AC XY: 62AN XY: 135906
GnomAD4 exome AF: 0.000259 AC: 378AN: 1461890Hom.: 1 Cov.: 34 AF XY: 0.000276 AC XY: 201AN XY: 727246
GnomAD4 genome AF: 0.000217 AC: 33AN: 152294Hom.: 0 Cov.: 33 AF XY: 0.000175 AC XY: 13AN XY: 74478
ClinVar
Submissions by phenotype
Hereditary pancreatitis Uncertain:3Benign:2
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 01, 2024 | - - |
Likely benign, criteria provided, single submitter | curation | Sema4, Sema4 | May 10, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Aug 14, 2020 | The CTRC c.674A>C; p.Glu225Ala variant (rs201486613) is described in the medical literature in individuals with pancreatitis (Beer 2013, Koziel 2015), but also described in unaffected individuals (Koziel 2015, Rosendahl 2008, Zhou 2011). This variant is reported in ClinVar (Variation ID: 240766). It is found in the general population with an overall allele frequency of 0.04% (115/282830 alleles, including 1 homozygote) in the Genome Aggregation Database. The glutamic acid at codon 225 is weakly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. Additionally, experiments in cell culture show this variant does not affect protein stability or activity (Beer 2013). Considering available information, there is insufficient evidence to classify this variant with certainty. References: Beer S et al. Comprehensive functional analysis of chymotrypsin C (CTRC) variants reveals distinct loss-of-function mechanisms associated with pancreatitis risk. Gut. 2013 Nov;62(11):1616-24. Koziel D et al. Genetic mutations in SPINK1, CFTR, CTRC genes in acute pancreatitis. BMC Gastroenterol. 2015 Jun 23;15:70. Rosendahl J et al. Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet. 2008 Jan;40(1):78-82. Zhou J et al. Chymotrypsin C mutations in chronic pancreatitis. J Gastroenterol Hepatol. 2011 Aug;26(8):1238-46. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 25, 2023 | The p.E225A variant (also known as c.674A>C), located in coding exon 7 of the CTRC gene, results from an A to C substitution at nucleotide position 674. The glutamic acid at codon 225 is replaced by alanine, an amino acid with dissimilar properties. This variant has been identified in individuals with pancreatitis and healthy controls (Rosendahl J et al. Nat. Genet., 2008 Jan;40:78-82; Koziel D et al. BMC Gastroenterol, 2015 Jun;15:70; Sofia VM et al. Mol. Med., 2016 Sep;22:300-309; Beer S et al. Gut, 2013 Nov;62:1616-24; Cordero-Vázquez E et al. Endocrinol Diabetes Nutr (Engl Ed), 2022 Feb;69:155-156). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Jun 28, 2018 | See Variant Classification Assertion Criteria. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at